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Introduction
The unusual physicochemical properties of fluorine, such as the small van der Waals radius, high electronegativity and the strength of the C-F bond make it a very important element in the pharmaceutical industry. Incorporation of fluorine into pharmacologically active compounds results in increased lipophilicity, improved metabolic stability and enhanced potency (Murphy and Sandford, 2015) . The importance of fluorine is reflected in the numbers of new fluorinated drugs that are either on the market or in development. In 2014 the US Food and Drug Administration approved 41 new molecular entities and of the 27 small molecules, eight contain fluorine (Jarvis, 2015) . Two examples are shown in Figure 1 : Sivextro® (tedizolid phosphate) is manufactured by Cubist Pharmaceuticals for the treatment of skin infections, and Zontivity® (vorapaxar) from Merck is an anti-clotting agent. Both drugs have a fluorophenyl substituted pyridyl moiety and the oxidative metabolism of this group has not been determined. Therefore, in this study the biotransformation of various fluorophenyl pyridine carboxylic acids was investigated in a fungus and microsomes to establish the phase I (oxidative) metabolites.
Cunninghamella spp. are fungi that have been used extensively as microbial models of drug metabolism for decades, in particular C. elegans, C. echinulata and C.
blakesleeana (Asha and Vidyavathi, 2009) . They are easily cultivated and have cytochrome P450 activity, which has a very broad substrate range (Murphy, 2015) , thus can yield phase I (oxidative) metabolites of many drugs, including those that contain fluorine Murphy, 2011) . They also have enzymes associated with phase II (conjugative) metabolism, such as sulfotransferase, glucosyl transferase and glutathione S-transferase (Zhang et al., 1996) . Furthermore, C. elegans can be employed in the design of fluorinated drugs, by identifying through biotransformation metabolically labile sites on non-fluorinated drug leads, which can then be modified by synthesis to contain fluorine at that specific position, thereby prolonging metabolic half-life (Bright et al., 2013 , Shaughnessy et al., 2014 . Amongst the many xenobiotics that Cunninghamella spp. can biotransform are nitrogencontaining heterocycles such as quinolone (Sutherland et al., 1994) , cinnoline (Sutherland et al., 1998) and phenothiazine (Sutherland et al., 2001) , and in the case of phenothiazine, the metabolites were analogous to those produced in mammals. In the present study the biotransformation of several fluorophenyl-substituted pyridine carboxylic acids ( Figure 2 ) by C. elegans was investigated, as a model of the likely phase I mammalian metabolism of drugs that contain similar functionalities, such as Sivextro and Zontivity. The catabolism of the compounds in rat liver microsomes was also investigated.
Materials and methods
Chemicals 5-Phenylpyridine-2-carboxylic acid 1 (95%) was acquired from Maybridge (Thermo Scientific). 5-(3-Fluorophenyl) pyridine-3-carboxylic acid 2, 5-(2-fluorophenyl) pyridine-3-carboxylic acid 3, 5-(4-fluorophenyl) pyridine-3-carboxylic acid 4, 6-(2fluorophenyl) pyridine-3-carboxylic acid 5, were purchased from Sigma Aldrich.
Culture conditions
Cunninghamella elegans was cultivated on sabouraud dextrose agar for 120 h at 27 °C.
Inoculum was prepared by homogenising the mycelium in sterile 0.8% NaCl (100 mL).
The homogenate (5 mL) was used to inoculate 250 mL Erlenmeyer flasks containing 45 mL sabouraud dextrose broth, then incubated 72 h with rotary agitation (150 rpm) at 28 °C. The compounds were solubilised in dimethyl sulfoxide, 50 μL was added to the flask and incubation was continued for a further 24 h (unless stated otherwise).
Supernatant from the biotransformation experiments was extracted in ethyl acetate; the solvent was removed under reduced pressure and the residue re-dissolved in methanol.
Isolation of biotransformation products
Organic extracts from shake flasks were analysed by reversed-phase high-performance liquid chromatography (HPLC) with a Varian prostar HPLC system equipped with Zorbax SB-C18 5 μm 4.6 × 150 mm column (Agilent technologies) and a UV-Vis detector monitoring at 250 nm. Analytes were eluted with a gradient of acetonitrile / water (20-80 % acetonitrile) over 35 min at a flow rate of 1 mL/min. The metabolites were purified by semi-preparative HPLC with an Ascentis C18 column (15 cm×10 mm, 5 µm Supelco), with a flow rate of 4mL/min for 35 minutes eluted with a gradient of acetonitrile containing trifluoroacetic acid (0.1% v/v)/water (20-80%). Fractions containing putative metabolite as indicated by UV absorbance, were pooled and extracted in ethyl acetate. To remove residual trifluoroacetic acid, the organic extracts were back extracted in an alkaline solution (pH 11). The isolated metabolites were confirmed by GC-MS and 19 F NMR.
Analysis of biotransformation products
Gas chromatography-mass spectrometry analysis was routinely conducted on per trimethylsilylated extracts using an Agilent 6890 gas chromatograph coupled to a 5973 mass selective detector. Silylation was performed by adding 50 μL N-methyl-N-(trimethyl-silyl) trifluoroacetamide (MSTFA, Sigma) to a dried aliquot of the extracted supernatant and heating at 100 °C for 1 h. Derivatised samples (1 µL) were injected in the split mode onto a HP-5MS column (30 m × 0.25 mm × 0.25 µm) and the oven temperature held at 150 ⁰C for 2 min then raised to 300 ⁰C at 10 ⁰C min -1 . The mass spectrometer was operated in scan mode. Accurate mass measurements were obtained with a LCT time-of-flight mass spectrometer (Waters Corp., USA). 19 F NMR, 1 H NMR and 13 C NMR spectra were recorded on Varian Inova 400 MHz or Agilent 126 and 500 MHz spectrometers with DMSO-d6 used as the solvent.
Chemical shifts (δ) are reported in ppm and coupling constants are given in Hz. 1 H signals were assigned using 2D homonuclear 1 H-1 H gradient COSY experiments. The 1 H coupling constants were determined by 1D 1 H spectra. 13 C signals were assigned using 2D heteronuclear 1 H-13 C and 19 F-13 C HSQC and 1 H-13 C HMBC experiments. The degree of transformation was determined by 19 F NMR spectroscopy of the crude reaction mixture. Inversion recovery experiments were performed to measure the relaxation time of the different compounds to improve accuracy of 19 F NMR analysis for quantitative measurement; consequently the relaxation delay was increased to 30 seconds. 
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Mammalian biotransformation
Methods employed in the transformation by rat liver microsomes were similar to that described by Obach et al (1998) . Rat liver microsomes (1 mg/mL) were incubated for 2 hours at 37 o C with the compounds 2-5 (0.5 mM, 0.25 mM, 0.125 mM) dissolved in DMSO (0.25% v/v), plus magnesium chloride (3.3 mM) and NADPH (1 mM) in a final volume of 0.5ml sodium phosphate buffer (25 mM, pH 7). The metabolites were extracted using ethyl acetate. Extracts were derivatised and analysed by GC-MS as described above except using splitless mode with the oven temperature held at 120 ⁰C for 2 min then raised to 300 ⁰C at 10 ⁰C min -1 . Control biotransformation experiments were conducted using flurbiprofen as the substrate. To measure the inhibition of the fluorophenyl pyridine carboxylic acids on rat liver microsomes, a co-incubation study using flurbiprofen (0.5 mM) and titrated concentrations of 2 were added as described above. 4'-Hydroxy-flurbiprofen was detected and the transformation efficiency was determined through integration of the peaks and expressed as a percentage of the combined areas of flurbiprofen and hydroxyflurbiprofen.
Results
Biotransformation of fluorophenyl pyridine carboxylic acids
Initial biotransformation products formed after 2-5 were incubated with the fungus were detected by 19 F NMR spectroscopy (Table 1) (Figure 4) . Similar reduction and oxidation of carboxyl groups has been observed in our previous study on biphenyl carboxylic acids (Bright et al., 2013) .
Site of mono-hydroxylation
Our previous studies on biphenyl systems , Bright et al., 2013 , Shaughnessy et al., 2014 demonstrated that the hydroxylation typically occurs on the 4' (para) position. Furthermore, when this site is blocked by fluorine, no hydroxylation occurs, and the observation that 4 was not biotransformed by the fungus is consistent with this. The hydroxylated fluorometabolites 8, 9 and 10 ( Figure 4 ) were further purified from the culture extracts by semi-preparative HPLC and subjected to structural characterisation by NMR. This revealed that the starting substrates 2, 3 and 5 were all hydroxylated in the expected 4' position, since the hydrogens H 7.54 (2), 7.52 ppm (3) and 7.37 ppm (5), disappear in the hydroxylated products. This was supported by the effect of the hydroxyl group on the splitting of the fluorine signal, changing its multiplicity to a doublet of doublets in each case and furthermore, by the strong coupling (12.5-13.5 Hz) between the fluorine atoms and their respective ortho hydrogens. For example, the coupling of the fluorine (12.5, 9 Hz) in metabolite 8, revealed that the hydrogen H 7.63 ppm assigned to the 2' position, shared a strong 3 JHF coupling (12.5 Hz). Whereas, its meta hydrogen, H 7.06 assigned to the 5' position shared a 4 JHF coupling of 9 Hz.
Mammalian biotransformation of fluorophenyl pyridine carboxylic acids
In order to compare the metabolites formed in the fungus with mammalian metabolites, compounds 2-5 were incubated with rat liver microsomes. However, no biotransformation products were detected by GC-MS. To determine if the fluorophenyl pyridine carboxylic acids are inhibitors of the microsomal preparations, various concentrations of 2 were incubated with microsomes plus another transformable substrate, flurbiprofen. GC-MS analysis of the ethyl acetate extracts demonstrated that in the absence of 2 or at a concentration of 0.125 mM of 2, the expected metabolite 4'hydroxyflurbiprofen was detected, but in the presence of 0.25 mM of 2, no metabolite was detected ( Figure 5) . Interestingly, when 0.125 mM of 2 was incubated with the microsomes, no biotransformation was observed, even though at this concentration the starting compound is not inhibitory to the hydroxylation of flurbiprofen.
Discussion
With the exception of the 4'-fluorinated derivative 4, C. elegans biotransformed various pyridine carboxylic acids 1-3 and 5 to phase I (oxidative) metabolites 8-10 that were hydroxylated on the fluorophenyl ring. Hydroxylated metabolites have been detected from similar bicyclic aromatic compounds incubated with this fungus, but none that contain the pyridyl moiety. Indeed, pyridine-containing substrates are often biotransformed to N-oxides by C. elegans (Parshikov et al., 2012) , and (Zeng et al., 2012) reported that 3-(N-Boc-aminomethyl)-5-bromopyridine was oxidized to the Noxide by C. echinulata. With the substrates 1-5 employed in this study (Figure 2 ) no Noxidation was observed.
The site of fluorine substitution had an influence on the extent of oxidation; thus compound 2, in which the fluorine is at C-3', was almost entirely biotransformed after 24 h incubation with C. elegans, whereas compound 3 (fluorine at C-2') was biotransformed to a much lesser degree and compound 4 (fluorine at C-4') was not biotransformed at all. Based on our previous studies with the related substrates fluorobiphenyl Murphy, 2010, Bright et al., 2013) and flurbiprofen , Shaughnessy et al., 2014 , the 4' position is predominantly hydroxylated and if replaced with fluorine, no hydroxylation is observed, which would account for the absence of hydroxylation of 4. Furthermore, 2, 3 and 5 were similarly regiospecifically hydroxylated at C4' by the fungus. Some researchers have correlated the regiospecificity of cytochrome P450catalysed hydroxylation of aromatic compounds with calculated frontier orbital density distribution (Koerts et al., 1997 , Rietjens et al., 1993 . Here, calculated frontier orbital density distributions at high-level computations (see supporting information for details) confirm the regiospecificity of CYP-catalysed hydroxylation for compounds 1-3 and 5
where the highest HOMO densities are found at the 4' carbon sites in these starting molecules. Interestingly, the calculated atomic charges (Table S1 ) for C4' of all the substrates reveal that compound 2 has the highest negative charge, which might account for this compound being most readily hydroxylated (Table 1) .
The site of phenyl ring substitution on pyridyl seems to determine whether the carboxyl is reduced, as in compounds 1 and 5, where the phenyl is para to the carboxyl group and yielded the corresponding alcohol after 24 h incubation. Only the carboxylic acid is observed after 48 h, thus the alcohol is re-oxidised. None of the other compounds (2-4), which had fluorophenyl substituents meta to the carboxyl group, were reduced in this way. Interestingly, fluorinated biphenyl-4-carboxylic acids underwent similar reduction and re-oxidation of the carboxylate when incubated with C. elegans (Bright et al., 2013) , but the hydroxylated alcohols were also detected as intermediates, whereas with the 1 and 5, only the hydroxylated carboxylic acids were identified. It is likely that a carboxylate reductase, which has been identified in other fungi (Winkler and Winkler, 2016, Ma et al., 2011) and requires ATP and NADPH as co-substrates, is responsible for the reduction. It is conceivable that as incubation time progresses and in the absence of any added nutrient, the redox balance in the cell results in the reverse reaction dominating, thus the carboxylic acid is produced.
Rat liver microsomes were unable to transform any of the fluorophenyl pyridine carboxylic acids, most likely because these compounds are inhibitors of the CYPs present. Pyridine inhibits rabbit liver microsomes (Kaul and Novak, 1987) and interestingly the N-oxide metabolite is formed, but no such metabolite was observed with 2. It is possible that the whole cells of C. elegans are more resilient to the inhibitory effects of the substrates in comparison to microsomes, which underscores the effectiveness of the fungal system as a mammalian proxy for in vitro assessment of xenobiotic biotransformation.
Studies of the human metabolism of voraxapar and tedizolid phosphate have revealed that the drugs are not degraded to a point where fluorophenyl pyridine is formed as a discrete metabolite (Ghosal et al., 2011; Ong et al., 2014) . Nevertheless, it is likely that this structural motif will be incorporated into future pharmaceutical agents, thus understanding the likely phase I metabolism arising from related model compounds, such as 2-5, will help in the prediction of the likely metabolites formed.
Conclusions
This study demonstrates that Cunninghamella elegans is able to produce hydroxylated metabolites of fluorophenyl pyridine carboxylic acids, and that the extent and regioselectivity of hydroxylation is dependent on the position of the fluorine substituent.
The absence of biotransformation products in microsomal incubations illustrates the usefulness of the fungus in generating difficult-to-obtain metabolites of relevant xenobiotics and drug-like molecules to enable a comprehensive understanding of their metabolism.
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